Details for Patent: 12,643,883

« Back to Dashboard

Which drugs does patent 12,643,883 protect, and when does it expire?

Patent 12,643,883 protects ROMVIMZA and is included in one NDA.

This patent has nine patent family members in nine countries.

Summary for Patent: 12,643,883

Title:	Solid state forms of a kinase inhibitor
Abstract:	Described herein, in part, are solid-state forms of the compound represented by Formula (I), pharmaceutical compositions comprising the solid-state forms, processes of making the solid-state forms and methods of using the solid-state forms
Inventor(s):	Elena Kostik, Michael D. Kaufman
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US19/421,407
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 12,643,883

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No	12,643,883		Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-002	Feb 14, 2025		RX	Yes	No	12,643,883		Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes	12,643,883		Y	Y

International Family Members for US Patent 12,643,883

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	134628
Australia	2024395016
Colombia	2026010018